OS Therapies Incorporated (OSTX) Research

OS Therapies Incorporated is a clinical-stage biopharmaceutical company dedicated to identifying, advancing, and commercializing therapeutic solutions for osteosarcoma and other solid tumors within the United States. Its pipeline highlights OST-HER2, a readily available immunotherapy developed for osteosarcoma patients, alongside OST-tunable drug conjugate (OST-tADC). This innovative antibody-drug conjugate technology leverages a modular 'plug-and-play' platform equipped with customizable, pH-sensitive silicone linkers. Established in 2018, OS Therapies Incorporated is headquartered in Rockville, Maryland.

Market snapshot

Symbol
OSTX
Price
$1.93
Day change
+12.21%
Market cap
$86.0M
P/E ratio
-2.12x
52-week range
1.15-2.57
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Recent news

  • OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory Filings

    OS Therapies Incorporated (NYSE:OSTX) shares are up during Tuesday's premarket session as the company recently announced that its Phase 2b trial of OST-HER2 achieved statistically significant overall survival results at the 2.5-year mark.

Peer companies

  • Adagene Inc. (ADAG)
  • Coeptis Therapeutics, Inc. (COEP)
  • CervoMed Inc. (CRVO)
  • Equillium, Inc. (EQ)
  • Werewolf Therapeutics, Inc. (HOWL)
  • MiNK Therapeutics, Inc. (INKT)
  • IO Biotech, Inc. (IOBT)
  • NRx Pharmaceuticals, Inc. (NRXP)

Recent insider activity

  • Romness Paul A. — A-Award (500000 shares) on 2024-12-05
  • McKean-Dieser Avril Suzette — A-Award (50000 shares) on 2026-01-22
  • Search Theodore F. — A-Award (50000 shares) on 2026-01-22
  • Ciccio John — A-Award (50000 shares) on 2026-01-22
  • Acevedo Christopher P. — A-Award (100000 shares) on 2026-01-22

Open OS Therapies Incorporated (OSTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.